|
|
|
|
|
Business FocusLactillion, as the holder of rights to multiple patents on the normal lactoferrin gene and protein, is poised to commercially utilize its intellectual property portfolio for the protection of its own products and for the generation of licensing revenue with other parties interested in producing lactoferrin. Market SummaryThe market for Lactillion's products is large and products that can save a person's life command substantial prices. Prevention of the progression of SIRS to sepsis would need to be given as early as possible after admission to the ICU. There are over 4.4 million ICU patients in the US each year. Prophylactic use would require daily administration for up to a week. Lactoferrin utilization rates would be considerably higher due to the known safety profile of the protein. Septic shock is the most common cause of mortality in the intensive care unit and is the 10th leading cause of death overall. Mortality ranges from 15% in patients with sepsis to 40-60% in patients with septic shock. There is a continuum of clinical manifestations from SIRS to sepsis to severe sepsis to septic shock to Multiple Organ Dysfunction Syndrome and eventual death. Market TrendsSepsis deaths have increased 82.6% from 1979 to 1997. Around 750,000 cases of sepsis are diagnosed per year, and around 31% of patients die. Shock develops in about 40% of septic patients. Annual health care cost for patients with sepsis is $5-10 billion. Sepsis is particularly dangerous for the elderly, and as the number of elderly is increasing in the U.S., Europe and Japan, there is a growing need to address this deadly condition. |
Lactillion
is currently engaged in raising financing. For further
information, please send your contact information and specific
interests:
Investor AdvantagesLactillion believes that it possesses several appealing characteristics for today’s funding environment:
|
 |
